-

Bio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2023 on Thursday, August 3, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.

To participate, call 888-259-6580 within the U.S., access code: 94809387. From outside the U.S., participants can join the call via the Audience Entry URL, access code: 94809387.

A live webcast of the conference call will also be available in the "Investor Relations" section of the company’s website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,300 employees and $2.8 billion in revenues in 2022. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

Contacts

Investor Contact:
Edward Chung, Investor Relations
510-741-6104
ir@bio-rad.com

Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
pr@bio-rad.com

Bio-Rad Laboratories, Inc.

NYSE:BIO

Release Versions

Contacts

Investor Contact:
Edward Chung, Investor Relations
510-741-6104
ir@bio-rad.com

Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
pr@bio-rad.com

More News From Bio-Rad Laboratories, Inc.

Bio-Rad Reports Third-Quarter 2025 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025. “During the third quarter, we continued to navigate a dynamic global environment and evolving conditions across the markets for our life science and clinical diagnostics products," stated Norman Schwartz, Bio-Rad's Chairman and CEO. "Despite ongoing challe...

Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2025 on Wednesday, October 29, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside th...

Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Alice N. Schwartz, Bio-Rad’s co-founder and Director Emeritus, passed away on September 25, 2025, at the age of 99. Mrs. Schwartz co-founded Bio-Rad in 1952 in Berkeley, California, together with her husband David Schwartz, shortly after graduating with a biochemistry degree from the University of California, Berkel...
Back to Newsroom